Treatment for multidrug-resistant tuberculosis: It's worse than we thought!

Clinical Infectious Diseases

Volumn 59, Issue 8, 2014, Pages 1064-1065

  Daley, Charles L ^a   Horsburgh, C Robert ^b  

^a DEPARTMENT OF MEDICINE   (United States)

^b BOSTON UNIVERSITY SCHOOL OF PUBLIC HEALTH   (United States)

Author keywords

Drug resistance; Extensively drug resistant tuberculosis; Green Light Committee; Multidrug resistant tuberculosis; Tuberculosis

Indexed keywords

QUINOLONE DERIVATIVE; TUBERCULOSTATIC AGENT;

EXTENSIVELY DRUG RESISTANT TUBERCULOSIS; HUMAN; MOLECULAR DIAGNOSIS; MORTALITY; MULTIDRUG RESISTANT TUBERCULOSIS; MYCOBACTERIUM TUBERCULOSIS; NOTE; PRIORITY JOURNAL; RESPIRATORY TRACT PARAMETERS; TREATMENT REFUSAL; TUBERCULOSIS CONTROL; FEMALE; MALE;

FEMALE; HUMANS; MALE;

EID: 84925279454     PISSN: 10584838     EISSN: 15376591     Source Type: Journal    
DOI: 10.1093/cid/ciu578     Document Type: Note

References (5)

1. World Health Organization. Global tuberculosis report 2013. Geneva, Switzerland: WHO, 2013.
2. Ahuja SD, Ashkin D, Avendano M, et al. Multidrug resistant pulmonary tuberculosis treatment regimens and patient outcomes: an individual patient data meta-analysis of 9,153 patients. PLoS Med 2012; 9:e1001300.
3. Falzon D, Gandhi N, Migliori GB, et al. Resistance to fluoroquinolones and second-line injectable drugs: impact on multidrug-resistant TB outcomes. Eur Resp J 2013; 42: 156-68.
4. Cegielski JP, Dalton T, Yagui M, et al. Extensive drug resistance acquired during treatment of multidrug-resistant tuberculosis. Clin Infect Dis 2014; 59:1049-63.
5. World Health Organization. The new global framework to support expansion of MDR-TB services and care. Available at: http://www.who. int/tb/challenges/mdr/greenlightcommittee/ en/. Accessed 18 July 2014.